685 reports of this reaction
3.6% of all RAVULIZUMAB reports
#3 most reported adverse reaction
HEADACHE is the #3 most commonly reported adverse reaction for RAVULIZUMAB, manufactured by Alexion Pharmaceuticals Inc.. There are 685 FDA adverse event reports linking RAVULIZUMAB to HEADACHE. This represents approximately 3.6% of all 19,021 adverse event reports for this drug.
Patients taking RAVULIZUMAB who experience headache should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HEADACHE is moderately reported among RAVULIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to headache, the following adverse reactions have been reported for RAVULIZUMAB:
The following drugs have also been linked to headache in FDA adverse event reports:
HEADACHE has been reported as an adverse event in 685 FDA reports for RAVULIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HEADACHE accounts for approximately 3.6% of all adverse event reports for RAVULIZUMAB, making it one of the most commonly reported side effect.
If you experience headache while taking RAVULIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.